January 2022 in “Asian journal of Current Research in Clinical Cancer” Some dibenzo compounds might help treat cancer with fewer side effects.
27 citations
,
May 2007 in “Archives of dermatological research” Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.
18 citations
,
April 2001 in “Bioorganic & Medicinal Chemistry Letters” The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
February 2026 in “Journal of Dermatological Treatment” CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
May 2026 in “Bioorganic Chemistry” 1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
1 citations
,
September 2022 Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
9 citations
,
August 2023 in “Molecules” Two peptides, RMYYY and VMYMI, may be effective anti-inflammatory drugs.
6 citations
,
February 2016 in “British Journal of Dermatology” A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
105 citations
,
August 2010 in “Pharmacology & therapeutics” Formyl-peptide receptor agonists could be new anti-inflammatory drugs.
12 citations
,
April 2023 in “Molecular Pharmaceutics” A new patch can deliver stable antibodies over time for potential HIV treatment.
January 2026 in “Journal of Dermatological Treatment” GT20029 showed some hair growth improvement, but longer studies are needed for better results.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
24 citations
,
December 2011 in “International Journal of Cancer” PTH-CBD agonists may help regrow hair after chemotherapy.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
2 citations
,
January 1994 in “Nihon Chikusan Gakkaiho” Cow colostrum and milk can effectively produce anti-hair keratin antibodies.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
Cepharanthine and tetrandrine show promise as COVID-19 drugs.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
6 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.